The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
3-(m-Tolyl)benzo[c]isoxazole-5-carboxylic Acid ID: ALA5186729
Chembl Id: CHEMBL5186729
PubChem CID: 168282264
Max Phase: Preclinical
Molecular Formula: C15H11NO3
Molecular Weight: 253.26
Associated Items:
Names and Identifiers Canonical SMILES: Cc1cccc(-c2onc3ccc(C(=O)O)cc23)c1
Standard InChI: InChI=1S/C15H11NO3/c1-9-3-2-4-10(7-9)14-12-8-11(15(17)18)5-6-13(12)16-19-14/h2-8H,1H3,(H,17,18)
Standard InChI Key: LFQODTOCTNJYMV-UHFFFAOYSA-N
Associated Targets(Human) Molecule Features Natural Product: NoOral: NoChemical Probe: NoParenteral: NoMolecule Type: Topical: NoFirst In Class: NoBlack Box: NoChirality: NoAvailability: NoProdrug: No
Drug Indications MESH ID MESH Heading EFO IDs EFO Terms Max Phase for Indication References
Mechanisms of Action Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References
Calculated Properties Molecular Weight: 253.26Molecular Weight (Monoisotopic): 253.0739AlogP: 3.50#Rotatable Bonds: 2Polar Surface Area: 63.33Molecular Species: ACIDHBA: 3HBD: 1#RO5 Violations: ┄HBA (Lipinski): 4HBD (Lipinski): 1#RO5 Violations (Lipinski): ┄CX Acidic pKa: 3.62CX Basic pKa: ┄CX LogP: 3.45CX LogD: 0.12Aromatic Rings: 3Heavy Atoms: 19QED Weighted: 0.76Np Likeness Score: -1.09
References 1. Zhou Y, Mukherjee S, Huang D, Chakraborty M, Gu C, Zong G, Stashko MA, Pearce KH, Shears SB, Chakraborty A, Wang H, Wang X.. (2022) Development of Novel IP6K Inhibitors for the Treatment of Obesity and Obesity-Induced Metabolic Dysfunctions., 65 (9.0): [PMID:35467861 ] [10.1021/acs.jmedchem.2c00220 ]